This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Retinoblastoma risk factors for recurrence

Retinoblastoma risk factors for recurrence
Reviewed by Fiona Rowe

7 April 2021 | Fiona Rowe (Prof) | EYE - Paediatrics, EYE - Strabismus
Share This

This study evaluates risk factors for local tumour recurrence of main solid tumour, subretinal seed, vitreous seed and new tumour formation in eyes with retinoblastoma (RB) management with primary chemotherapy over 20 years of follow-up. The study included 960 eyes and 551 patients with RB management by primary chemotherapy. Ninety-five other eyes were excluded due to insufficient follow-up; 556 eyes of 408 patients developed some recurrence versus 313 eyes of 262 patients with no recurrence. Recurrence was more with younger mean age at presentation (10 versus 13 months) and with more advanced disease, greater number of tumours per eye, greater main largest tumour basal diameter and thickness, shorter mean tumour distance to foveola and optic disc and lower frequency of no subretinal seeds or fluid. Recurrence cases had more frequent requirement for additional globe-sparing treatment. Recurrence cases included 355 with main tumour recurrence, 244 with subretinal seeds, 162 with vitreous seeds and 118 with new tumour. Recurrence had more frequent need for enucleation. Most recurrence or new tumours were detected within the first three years of treatment. This study has identified those at greatest risk of recurrence. This is important as newer, targeted treatment can be implemented to treat most without enucleation.

Risk factors for tumor recurrence following primary IV chemotherapy (chemoreduction) for retinoblastoma in 869 eyes of 551 patients.
Dalvin LA, Bas Z, Tadepalli S, et al.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2020;57:224-34.
Share This
Fiona Rowe (Prof)
CONTRIBUTOR
Fiona Rowe (Prof)

Institute of Population Health, University of Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency